GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » EV-to-EBITDA

Theseus Pharmaceuticals (Theseus Pharmaceuticals) EV-to-EBITDA : 0.30 (As of Apr. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Theseus Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Theseus Pharmaceuticals's enterprise value is $-20.19 Mil. Theseus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-66.44 Mil. Therefore, Theseus Pharmaceuticals's EV-to-EBITDA for today is 0.30.

The historical rank and industry rank for Theseus Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

THRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76959.21   Med: 0   Max: 17668.68
Current: 0.3

During the past 4 years, the highest EV-to-EBITDA of Theseus Pharmaceuticals was 17668.68. The lowest was -76959.21. And the median was 0.00.

THRX's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.1 vs THRX: 0.30

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Theseus Pharmaceuticals's stock price is $4.06. Theseus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.340. Therefore, Theseus Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Theseus Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Theseus Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals EV-to-EBITDA Chart

Theseus Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
- - -9.00 0.02

Theseus Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 0.02 -2.55 -3.07 1.27

Competitive Comparison of Theseus Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Theseus Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theseus Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theseus Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Theseus Pharmaceuticals's EV-to-EBITDA falls into.



Theseus Pharmaceuticals EV-to-EBITDA Calculation

Theseus Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-20.190/-66.441
=0.30

Theseus Pharmaceuticals's current Enterprise Value is $-20.19 Mil.
Theseus Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theseus Pharmaceuticals  (NAS:THRX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Theseus Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.06/-1.340
=At Loss

Theseus Pharmaceuticals's share price for today is $4.06.
Theseus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.340.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Theseus Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
245 Main Street, Cambridge, MA, USA, 02142
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms officer: Chief Financial Officer C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson director, officer: President and CEO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein director 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare officer: See Remarks 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp 10 percent owner 190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd. 10 percent owner 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022